Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Development > MTRN-2696

MTRN-2696Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Vinca Alkaloid

Target Indications

  • Solid Tumors

Route of Administration

  • Oral

Mode of Action

MTRN-2696 is based on metronomic chemotherapy. MTRN-2696 is administrered frequently by oral route at doses that are significantly lower than MTD.

Status

  • Phase 1 trials

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Metronomic TherapySpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

SPI-1620

The concept of metronomic chemotherapy: giving people long-term chemotherapeutic agents at relatively low doses, and with no drug-free breaks. The doses are low enough that side effects are not a major problem.

The metronomic chemotherapy philosophy stands in contradiction to traditional chemotherapy regimens, which called for higher doses often limited largely by the body’s capacity to handle the side effects, and for limited campaigns of several weeks in order to avoid drug resistance and avoid harming the body’s organs beyond a certain limit. Metronomic chemotherapy uses cytotoxic drugs but counts on them to stop or slow blood vessel growth. The name metronomic comes from the idea of regular administration of the drug. It stands as a different philosophy from the maximum tolerated dose (MTD) method typically used.